Crofelemer Dosing for Diarrhea Management
The recommended dosing regimen for crofelemer is 125 mg taken orally twice daily, with or without food, and tablets must be swallowed whole without crushing or chewing 1.
FDA-Approved Indication and Dosing
Crofelemer (Mytesi) is FDA-approved specifically for symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy 1. The standard dose of 125 mg twice daily was selected through a prospective two-stage clinical trial design that compared 125 mg, 250 mg, and 500 mg doses, with the 125 mg twice-daily regimen demonstrating optimal efficacy and tolerability 2.
Key Dosing Considerations:
Before initiating crofelemer, infectious etiologies of diarrhea must be ruled out 1. This is critical because crofelemer is not indicated for infectious diarrhea, and treating infectious causes with an antisecretory agent could delay appropriate antimicrobial therapy and worsen outcomes 1.
Administration: Take with or without food; food does not affect systemic exposure (though absorption is minimal regardless) 1
Tablet integrity: Do not crush or chew—swallow whole to maintain the delayed-release formulation 1
No dose adjustments are needed based on CD4 count or HIV viral load 1
Mechanism and Clinical Context
Crofelemer works by inhibiting both CFTR (cystic fibrosis transmembrane conductance regulator) and calcium-activated chloride channels in the intestinal lumen, thereby blocking chloride and water secretion that causes secretory diarrhea 1. Because it acts locally in the gastrointestinal tract with minimal systemic absorption (plasma concentrations below quantitation limits of 50 ng/mL), it has a favorable safety profile with minimal drug interactions 1.
Efficacy Data:
In the pivotal ADVENT trial, 17.6% of patients on crofelemer 125 mg twice daily achieved clinical response (≤2 watery stools/week for ≥2 of 4 weeks) versus 8.0% on placebo (P=0.01) 2. During the 20-week open-label extension, weekly response rates ranged from 40-56% 2.
Emerging Applications (Investigational)
While FDA-approved only for HIV-associated diarrhea, crofelemer is being investigated for chemotherapy-induced diarrhea:
Cancer therapy-related diarrhea: Studies in HER2-positive breast cancer patients receiving pertuzumab-based regimens used the same 125 mg twice daily dosing prophylactically, showing reduced incidence and severity of grade ≥2 diarrhea 3, 4
Neratinib-induced diarrhea: The 125 mg twice daily dose demonstrated activity, with most patients controlling diarrhea with crofelemer alone 4
Important Caveats:
Not a substitute for rehydration: Like all antidiarrheal agents, crofelemer does not replace fluid and electrolyte therapy, which remains the cornerstone of diarrhea management 5
Pediatric use: Safety and effectiveness have not been established in pediatric patients 1
Contraindications: None listed, but must exclude infectious causes first 1
Common adverse effects: Upper respiratory tract infection (8%), bronchitis (4%), cough (4%), flatulence (3%), and notably constipation (82% in one study, though all grade 1) 1, 4
The 125 mg twice-daily dose represents a carefully validated regimen that balances efficacy, safety, and practicality for managing chronic non-infectious secretory diarrhea in the approved HIV/AIDS population, with emerging evidence supporting its use in chemotherapy-induced diarrhea at the same dosing schedule.